Nuclear medicine funding a win for men with prostate cancer
Australian men with higher risk prostate cancer now have access to a nuclear medicine scan to help detect and treat metastatic disease, after it was listed on the Medical Benefits Schedule (MBS) from 1st July 2022.
In 2021 over 18,000 Australian men were diagnosed with prostate cancer, resulting in over 3,000 lives being lost – and making prostate cancer Australia’s second most common cause of cancer death in men.
Australian Health Journal spoke with AANMS President Associate Professor Sze Ting Lee and Dr Geoff Schembri on the MBS listing and the efforts to get it listed.